Use of Hormone Replacement Therapy and Risk of Dementia: A Nationwide Cohort Study
- PMID: 36240091
- DOI: 10.1212/WNL.0000000000200960
Use of Hormone Replacement Therapy and Risk of Dementia: A Nationwide Cohort Study
Abstract
Background and objectives: Estrogen has the potential to influence brain physiology implicated in dementia pathogenesis. Hormone replacement therapy (HRT) might be expected to influence the risk of dementia. Observational data indicated that HRT was associated with reductions in dementia risk, but experimental evidence demonstrates that HRT increases the incidence of dementia. To determine the effect of HRT on the risk of dementia, a retrospective cohort study was performed using a nationwide claims dataset in Taiwan.
Methods: A population-based longitudinal study was performed using data from the Longitudinal Health Insurance Database in Taiwan. A total of 35,024 women with HRT were enrolled as the exposed cohort and 70,048 women without HRT were selected on the basis of propensity matching as the comparison cohort. All participants were followed up until the diagnosis of dementia, death, or at the end of December 31, 2013, whichever occurred first. Overall, the average duration of follow-up (±SD) in the HRT and comparison cohorts was 12.3 (±2.3) and 12.2 (±2.4), respectively. The Cox proportional hazards regression models were conducted to produce hazard ratios (HRs) with 95% CIs to evaluate the association of HRT with the risk of dementia.
Results: In the follow-up period, the cumulative incidence of dementia for the HRT cohort (20.04 per 1,000) was significantly higher than the corresponding cumulative incidence for the comparison cohort (15.79 per 1,000), resulting in an adjusted HR of 1.35 (95% CI 1.13-2.62). There was an increased risk of dementia with a higher cumulative dose of HRT prescription (p for trend <0.0001).
Discussion: This cohort study documented that HRT was associated with an increased risk of dementia. The clinical implications of this study merit further investigations.
© 2022 American Academy of Neurology.
Similar articles
-
Hormone Replacement Therapy and the Incidence of Nonarteritic Anterior Ischemic Optic Neuropathy: a Nationwide Population-Based Study (2009-2018).Graefes Arch Clin Exp Ophthalmol. 2023 Jul;261(7):2019-2029. doi: 10.1007/s00417-023-05976-8. Epub 2023 Jan 21. Graefes Arch Clin Exp Ophthalmol. 2023. PMID: 36680611
-
The Risk of Breast Cancer in Women Using Menopausal Hormone Replacement Therapy in Taiwan.Int J Environ Res Public Health. 2016 May 11;13(5):482. doi: 10.3390/ijerph13050482. Int J Environ Res Public Health. 2016. PMID: 27187426 Free PMC article.
-
Menopausal hormone therapy and risk for dementia in women with CKD: A nationwide observational cohort study.Nephrology (Carlton). 2024 Mar;29(3):126-134. doi: 10.1111/nep.14260. Epub 2023 Dec 13. Nephrology (Carlton). 2024. PMID: 38092706
-
Postmenopausal hormone replacement therapy: scientific review.JAMA. 2002 Aug 21;288(7):872-81. doi: 10.1001/jama.288.7.872. JAMA. 2002. PMID: 12186605 Review.
-
Hormone replacement therapy to maintain cognitive function in women with dementia.Cochrane Database Syst Rev. 2002;(3):CD003799. doi: 10.1002/14651858.CD003799. Cochrane Database Syst Rev. 2002. Update in: Cochrane Database Syst Rev. 2009 Jan 21;(1):CD003799. doi: 10.1002/14651858.CD003799.pub2 PMID: 12137718 Updated. Review.
Cited by
-
Alzheimer Disease and Related Dementia Following Hormone-Modulating Therapy in Patients With Breast Cancer.JAMA Netw Open. 2024 Jul 1;7(7):e2422493. doi: 10.1001/jamanetworkopen.2024.22493. JAMA Netw Open. 2024. PMID: 39012631 Free PMC article.
-
Risks and benefits of hormone therapy after menopause for cognitive decline and dementia: A conceptual review.Maturitas. 2024 Jun;184:108003. doi: 10.1016/j.maturitas.2024.108003. Epub 2024 Apr 17. Maturitas. 2024. PMID: 38649310 Review.
-
Towards a Unitary Hypothesis of Alzheimer's Disease Pathogenesis.J Alzheimers Dis. 2024;98(4):1243-1275. doi: 10.3233/JAD-231318. J Alzheimers Dis. 2024. PMID: 38578892 Free PMC article.
-
Cancer drugs with high repositioning potential for Alzheimer's disease.Expert Opin Emerg Drugs. 2023 Dec;28(4):311-332. doi: 10.1080/14728214.2023.2296079. Epub 2023 Dec 26. Expert Opin Emerg Drugs. 2023. PMID: 38100555 Review.
-
Hippocampal glial inflammatory markers are differentially altered in a novel mouse model of perimenopausal cerebral amyloid angiopathy.Front Aging Neurosci. 2023 Nov 15;15:1280218. doi: 10.3389/fnagi.2023.1280218. eCollection 2023. Front Aging Neurosci. 2023. PMID: 38035277 Free PMC article.
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical